CClinicalTrials.gg
CompletedNCT06635369Updated Oct 10, 2024

Taurine in Periodontitis and Aging

An interventional study of Periodontal Indices in Peridontal Disease and Aging, sponsored by Istanbul Medipol University Hospital. Completed at 1 site in Turkey. Open to participants aged 26 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-10.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2023, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
26 Years and older
Sex
All
01

Study summary

Aging leads to a decline in physiological functions and increases the risk of chronic diseases. Periodontitis is a chronic inflammatory disease that causes progressive destruction of the tissues supporting the teeth. Taurine, an amino acid with anti-inflammatory and antioxidant effects, might impact both periodontitis and aging. This study investigated taurine, SIRT1, and TNF-α levels in saliva and blood of 66 healthy people in different age groups, with or without periodontal disease. The findings showed that young people with healthy periodontal status had higher levels of taurine and SIRT1 compared to others. TNF-α, a marker of inflammation, was linked to the severity of periodontitis and may help identifying it in younger individuals. Overall, higher TNF-α levels are associated with periodontal inflammation, while taurine levels decrease with age-related inflammation.

02

Conditions studied

  • Peridontal Disease
  • Aging

Browse trials for

Keywords

  • Taurine
  • Periodontitis
  • Aging
  • Inflammation
  • TNF-α
  • SIRT1
  • Biomarker
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's enrollment of 66 is above the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Istanbul Medipol University Hospital is the lead sponsor of 350 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
26 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Exclusion Criteria:

  • ages 18-25 or 45-64
  • use of antibiotics, anti-inflammatory drugs, immunosuppressants, beta-blockers, calcium channel blockers, or anticoagulants within the last 6 months
  • presence of diabetes, rheumatoid arthritis, or other systemic conditions such as cardiovascular, renal, hepatic, and neurodegenerative disorders
  • pregnancy or lactation
  • alcoholism
  • smoking
  • nonsurgical periodontal treatment in the past 6 months or surgical treatment in the past 12 months
  • having less than 20 natural teeth, excluding third molars
  • use of orthodontic appliances
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Young (25-44 years) with a healthy periodontium

    Diagnostic Test: Periodontal Indices

  • Experimental
    young (25-44 years) with Periodontitis

    Diagnostic Test: Periodontal Indices

  • Experimental
    Old (≥65 years) with a healthy periodontium

    Diagnostic Test: Periodontal Indices

  • Experimental
    Old (≥65 years) with Periodontitis

    Diagnostic Test: Periodontal Indices

Interventions

  • Diagnostic testPeriodontal Indices

    Saliva, serum and periodontal indexes were obtained from patients

    Also known as: Salivary Flow Rate, TNF-α Levels, SIRT1 Levels, Taurine Levels

06

What researchers measure

Primary outcomes

  1. Taurine

    Taurine levels in saliva and serum were measured

    Time frame: 12 Weeks

  2. SIRT1

    SIRT1 levels in saliva and serum were measured

    Time frame: 12 Weeks

  3. TNF-α

    TNF-α levels in saliva and serum were measured

    Time frame: 12 Weeks

07

Study locations

1 site
  • Istanbul Medipol University
    Istanbul, Unkapani, Turkey
08

References and documents

Individual participant data

Plan to share: No — Due to patients data privacy

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06635369
Lead sponsor
Istanbul Medipol University Hospital
Responsible party
Hadi Sayedyousef (Phd candidate, Istanbul Medipol University Hospital) — Principal investigator
First posted
Oct 10, 2024
Start date
Dec 21, 2023
Primary completion
May 1, 2024
Completion
Jun 1, 2024
Last update
Oct 10, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion